Analytical Pharmacology Core

分析药理学核心设施共享资源 摘要 分析药理学核心设施(APCF)鼓励和促进 为基础科学家和临床医生提供全面的分析和咨询服务 环境。APCF协助设计和实施药代动力学、药效学和 小分子和生物制剂临床和临床前研究中的生物标记物相关性研究 (例如，抗体、反义寡核苷酸、疫苗和细胞疗法)。 提供的主要服务包括：1)定量分析开发和样品分析(LC-MS/MS、ICP-MS、 药物、生物标志物和相关化合物的GC/MS、HPLC、Luminex、ELISA、qPCR)；2)研究设计和 药代动力学和生物标志物数据的专家分析。 所有主要的分析设备都被整合到夏皮罗大楼的一个连续的房间里。最多的 核心内使用最多的主要设备是LC-MS/MS仪器和FLEXMAP 3D多路复用器 免疫分析平台。质谱仪包括一个微质量四元组终极三元组，一个 Waters Quattro Premier XE Triple Quad，AB Sciex QTRAP 5500，Agilent 6410，以及最近收购的 Waters Xevo-TQXS。所有系统都为检测和量化提供最先进的选择性和灵敏度 复杂生物基质中的分析物，并与高效液相前端组件对接。额外的密钥核心 设备包括安捷伦8800电感耦合等离子体三重四极杆质谱仪(ICPMS) 用于金属和含金属化合物的测定，以及四个完整的高效液相系统。用于分析 生物制剂，核心有一个FLEXMAP 3D BioPlex仪器，用于多重免疫分析，Bio-Rad 用于基因表达绝对定量的QX200水滴数字聚合酶链式反应，FLOOSTAR OPTIMA多标记板 用于广泛的高通量ELISA应用的阅读器，以及番石榴PCA-96分析细胞分析仪。 核心由癌症生物学系教授蒂莫西·西诺德博士指导，由 一个跨学科的教师咨询委员会。西诺德博士积极参与了大多数早期药物的研究 血液科和内科肿瘤科的发展努力，这反映在沉重的 DCT和HM计划成员的使用情况。每年通过用户调查提供用户反馈。 自上一次竞争延长以来，基金为CC成员出版的44份出版物提供了捐助。在过去五年中 多年来，APCF共有74名独立调查人员使用，其中包括来自所有五个方案的56名CC成员。 在56个协调委员会成员中，46个(82%)获得了同行审查的资金。在此期间，147种独特的分析方法 被开发或重新启动，分析了24,502个样品。此外，还收集了4632份临床标本 核心支持了已处理和75项单独的癌症临床试验。

Analytical Pharmacology Core Facility Shared Resource ABSTRACT The Analytical Pharmacology Core Facility (APCF) encourages and facilitates collaborative research between basic scientists and clinicians by providing comprehensive analytical and consultative services in a GLP-capable environment. The APCF assists with the design and implementation of pharmacokinetic, pharmacodynamic, and biomarker correlative studies for clinical and preclinical investigations of small molecules and biologic agents (e.g., antibodies, antisense oligonucleotides, vaccines, and cellular therapeutics). Primary services provided are: 1) quantitative assay development and sample analysis (LC-MS/MS, ICP-MS, GC/MS, HPLC, Luminex, ELISA, qPCR) of drugs, biomarkers, and related compounds; and 2) study design and expert analysis of pharmacokinetic and biomarker data. All major analytical equipment is consolidated into a contiguous suite of rooms in the Shapiro building. The most heavily utilized major equipment within the core are the LC-MS/MS instruments and the FLEXMAP 3D multiplex immunoassay platform. Mass spectrometry instrumentation includes a Micromass Quattro Ultima triple quad, a Waters Quattro Premier XE triple quad, an AB Sciex QTRAP 5500, an Agilent 6410, and a recently acquired Waters Xevo-TQXS. All systems provide state-of-the-art selectivity and sensitivity for detecting and quantifying analytes in complex biological matrices and are interfaced with HPLC front-end components. Additional key core equipment include an Agilent 8800 inductively-coupled plasma triple quadrupole mass spectrometer (ICP-MS) for determination of metals and metal-containing compounds and four complete HPLC systems. For analysis of biological agents, the Core has a FLEXMAP 3D Bioplex instrument for multiplex immunoassays, a Bio-Rad QX200 Droplet Digital PCR for absolute quantitation of gene expression, a FLUOstar OPTIMA multi-label plate reader for a wide range of high-throughput ELISA applications, and a Guava PCA-96 analytical cell analyzer. The core is directed by Dr. Timothy Synold, a Professor in the Department of Cancer Biology, with oversight by an interdisciplinary faculty Advisory Committee. Dr. Synold actively participates in most of the early drug development efforts within the Divisions of Hematology and Medical Oncology, which is reflected in the heavy usage by members of the DCT and HM Programs. User feedback is provided annually through user surveys. Since the last competitive renewal, the APCF contributed to 44 publications by CC members. Over the past five years, the APCF was used by a total of 74 unique investigators, including 56 CC members from all five Programs. Of the 56 CC members, 46 (82%) had peer-reviewed funding. During this period, 147 unique analytical methods were developed or re-initiated and 24,502 samples were analyzed. In addition, 4,632 clinical specimens were processed and 75 separate cancer clinical trials were supported by the core.